Individualization of treatment strategies
- 16 September 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Advances in Therapy
- Vol. 28 (S6), 19-38
- https://doi.org/10.1007/s12325-011-0033-1
Abstract
This section focuses on different aspects of the individualization of hormone treatment in breast cancer. This includes tumor-related biological factors such as expression of hormone receptors, HER-2, and Ki-67; host-related factors such as CYP2D6 or body mass index, and risk and/or development of specific toxicities and treatment adherence. The best predictor of response to hormonal interventions is the expression of hormone receptors, in particular, estrogen receptors. Treatment adherence and compliance are key factors and strategies aiming to identify and intervene when patients are at risk of abandoning treatment. Currently, routine assessment of CYP2D6 is not recommended to guide tamoxifen treatment. Likewise, there are no criteria regarding bone mass density, lipid profile, or arthralgias to recommend one class of agent versus another. Aromatase inhibitors should not be administered to patients who are pre- or perimenopausal.This publication has 63 references indexed in Scilit:
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast CancerThe New England Journal of Medicine, 2009
- Feasibility Trial of Electroacupuncture for Aromatase Inhibitor—Related Arthralgia in Breast Cancer SurvivorsIntegrative Cancer Therapies, 2009
- Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancerAnnals of Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerThe New England Journal of Medicine, 2009
- The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2Nature Clinical Practice Oncology, 2008
- Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal womenBreast Cancer Research, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerThe New England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerThe New England Journal of Medicine, 2003